Oliver Luxxe Assets LLC Invests $8.52 Million in Astrazeneca Plc $AZN

Oliver Luxxe Assets LLC bought a new stake in shares of Astrazeneca Plc (NYSE:AZN) during the 2nd quarter, HoldingsChannel.com reports. The firm bought 45,272 shares of the company’s stock, valued at approximately $8,518,000. Astrazeneca comprises approximately 1.3% of Oliver Luxxe Assets LLC’s portfolio, making the stock its 24th largest holding.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Brighton Jones LLC increased its holdings in shares of Astrazeneca by 93.2% during the fourth quarter. Brighton Jones LLC now owns 5,782 shares of the company’s stock worth $379,000 after buying an additional 2,789 shares in the last quarter. AQR Capital Management LLC boosted its holdings in shares of Astrazeneca by 45.3% in the 1st quarter. AQR Capital Management LLC now owns 37,501 shares of the company’s stock worth $2,756,000 after acquiring an additional 11,690 shares in the last quarter. Amundi boosted its holdings in shares of Astrazeneca by 54.4% in the 2nd quarter. Amundi now owns 10,274 shares of the company’s stock worth $731,000 after acquiring an additional 3,618 shares in the last quarter. Jump Financial LLC grew its position in Astrazeneca by 898.4% during the 2nd quarter. Jump Financial LLC now owns 33,478 shares of the company’s stock worth $2,339,000 after acquiring an additional 30,125 shares during the last quarter. Finally, Daiwa Securities Group Inc. grew its position in Astrazeneca by 1.2% during the 2nd quarter. Daiwa Securities Group Inc. now owns 46,642 shares of the company’s stock worth $3,259,000 after acquiring an additional 559 shares during the last quarter. Institutional investors own 20.35% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently commented on AZN shares. Deutsche Bank Aktiengesellschaft restated a “sell” rating on shares of Astrazeneca in a report on Tuesday, June 30th. DZ Bank upgraded shares of Astrazeneca from a “neutral” rating to a “buy” rating in a research report on Wednesday, April 29th. HSBC lowered shares of Astrazeneca from a “buy” rating to a “hold” rating in a report on Monday, July 13th. Barclays restated a “buy” rating on shares of Astrazeneca in a research report on Monday, June 1st. Finally, Wall Street Zen downgraded shares of Astrazeneca from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. Twelve research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $211.00.

Astrazeneca Stock Performance

AZN stock opened at $161.28 on Friday. Astrazeneca Plc has a twelve month low of $145.79 and a twelve month high of $212.71. The company has a quick ratio of 0.67, a current ratio of 0.89 and a debt-to-equity ratio of 0.47. The company has a market cap of $250.12 billion, a P/E ratio of 24.11, a price-to-earnings-growth ratio of 1.39 and a beta of 0.26. The business’s fifty day moving average is $176.34 and its 200-day moving average is $187.12.

Astrazeneca (NYSE:AZN) last posted its earnings results on Monday, July 27th. The company reported $2.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.50 by $0.13. Astrazeneca had a return on equity of 31.45% and a net margin of 17.02%.The company had revenue of $15.38 billion during the quarter, compared to analyst estimates of $15.44 billion. During the same period in the previous year, the company earned $2.17 EPS. The company’s revenue for the quarter was up 6.4% compared to the same quarter last year. Equities research analysts forecast that Astrazeneca Plc will post 10.22 EPS for the current year.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.